COSCIENS Biopharma IncNASDAQ:CSCIView on Canadian Exchange
- LAST PRICE4.0000
- TODAY'S CHANGE (%)-0.1000 (-2.4390%)
- Bid / Lots4.0000/ 9
- Ask / Lots4.3100/ 11
- Open / Previous Close4.1300 / 4.1000
- Day Range
- 52 Week Range
- Volume2,910
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSCI |
|---|---|---|
| 09:43 ET | 400 | 4.13 |
| 09:48 ET | 1402 | 4.13 |
| 11:26 ET | 100 | 4 |
| 12:20 ET | 600 | 4 |
Aug 27, 2024
DJ Cosciens Biopharma Shares Drop After Trial Misses Key Target, from 10:09AM ET on Tuesday Aug 27, 2024 by Dow Jones
10:09AM ET on Tuesday Aug 27, 2024 by Dow JonesDJ Cosciens Biopharma Study of Macimorelin for Children Misses Primary Efficacy Endpoint, from 7:57AM ET on Tuesday Aug 27, 2024 by Dow Jones
7:57AM ET on Tuesday Aug 27, 2024 by Dow JonesCOSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency, from 7:30AM ET on Tuesday Aug 27, 2024 by Dow Jones
7:30AM ET on Tuesday Aug 27, 2024 by Dow Jones
Aug 13, 2024
*DJ COSCIENS Biopharma 2Q Rev $2.3M >CSCI, from 8:07AM ET on Tuesday Aug 13, 2024 by Dow Jones
8:07AM ET on Tuesday Aug 13, 2024 by Dow JonesCOSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results, from 8:05AM ET on Tuesday Aug 13, 2024 by Dow Jones
8:05AM ET on Tuesday Aug 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
COSCIENS Biopharma Inc | 20.5M | -0.4x | --- |
Evogene Ltd | 14.9M | -0.8x | --- |
Synlogic Inc | 16.1M | -0.2x | --- |
OpGen Inc | 16.9M | -0.1x | --- |
Plus Therapeutics Inc | 8.0M | -0.4x | --- |
Palatin Technologies Inc | 23.1M | -0.6x | --- |
Company Information
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
Contact Information
- Headquarters
- C/O Norton Rose Fulbright Canada Llp 222 Bay Street, Suite 3000,TORONTO, ON, Canada M5K 1E7
- Phone
- 418-652-8525
- Fax
- 418-948-9191
Executives
- Chairman of the Board
- Ronald Miller
- President, Chief Executive Officer, Director
- Gilles Gagnon
- Chief Financial Officer, Senior Vice President, Director
- Giuliano La Fratta
- Director
- Carolyn Egbert
- Director
- Genevieve Foster
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.1M |
|---|---|
Revenue (TTM) | $4.5M |
Shares Outstanding | 3.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-9.36 |
Book Value | $14.99 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 3.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -365.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
